Shanghai Pharmaceuticals Issues Unaudited 2026 First-Quarter Results Announcement

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an announcement.

Shanghai Pharmaceuticals Holding Co., Ltd., a major PRC-based pharmaceutical manufacturer and distributor listed in Hong Kong, has released its unaudited first quarterly report for 2026 prepared under PRC Accounting Standards for Business Enterprises. The board, senior management and key accounting officers formally attest to the truthfulness, accuracy and completeness of the financial statements, underscoring regulatory compliance and governance obligations to Hong Kong investors.

The company confirms that the first-quarter financial statements have not been audited, a common practice for interim disclosures in the market. The announcement also reiterates the current composition of the board, highlighting the mix of executive, non-executive, employee and independent non-executive directors, which is relevant to investors tracking oversight, accountability and corporate governance structure.

The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China with limited liability, whose shares are listed on the Hong Kong Stock Exchange under stock code 02607. The group operates in the pharmaceutical industry, focusing on the manufacture, distribution and related services of pharmaceutical products in the domestic Chinese market and internationally through its Hong Kong listing.

Average Trading Volume: 2,318,784

Technical Sentiment Signal: Hold

Current Market Cap: HK$64.19B

Learn more about 2607 stock on TipRanks’ Stock Analysis page.